Last updated: 2026-09-05 18:16:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
bioAffinity Technologies, Inc. (BIAF) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $15.30, with a market capitalization of $5.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.56 to $202.50. This page covers its latest market performance, valuation, price trends and company information.
$5.78M | |
$11.58 | |
$6,997.50 | |
$4.56 | |
$12.78 | |
18.59M | |
-- | |
-- | |
$202.50 | |
$4.56 | |
-- | |
-- |
bioAffinity Technologies, Inc. (BIAF) last closed at $12.78 as of 2026-09-05 00:01:00, unchanged from the previous close of $12.78.
During the latest regular trading session, BIAF traded between $4.56 and $6,997.50, with a volume of 18.59M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, bioAffinity Technologies, Inc. (BIAF) moved from $4.83 to $15.30, representing a gain of 216.75% ($10.47).
The stock traded between $10.95 and $20.01 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 18.84 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.4%
BIAF is currently trading at $15.30, placing it 5.4% of the way from its 52-week low of $4.56 to its 52-week high of $202.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of bioAffinity Technologies, Inc. (BIAF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.